Tarsus Pharmaceuticals, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. Although the request identifies 2020 Q4, this annual filing reports full-year results; it does not provide a clear standalone fourth-quarter income statement or cash flow.
Business context
Tarsus is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. Its lead candidate, TP-03 (lotilaner eye drops), is in pivotal development for Demodex blepharitis. Other programs target meibomian gland disease (MGD), rosacea, Lyme disease prevention, and malaria transmission reduction.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | No product revenue | No product revenue |
| Research and development expense | $18.8 million | $3.2 million |
| General and administrative expense | $8.2 million | $1.1 million |
| Total operating expenses / operating loss | $27.0 million | $4.3 million |
| Net loss | $26.8 million | $4.7 million |
| Net loss per share, basic and diluted | $4.32 | $1.98 |
| Net cash used in operating activities | $21.1 million | $3.7 million |
| Cash and cash equivalents at year-end | $168.1 million | $58.0 million |
| Working capital at year-end | $165.3 million | $57.2 million |
| Total liabilities at year-end | $6.0 million | $0.9 million |
Cash flow from financing activities was $131.8 million in 2020, principally reflecting $91.7 million of net IPO proceeds and $39.8 million from Series C preferred stock. Investing cash outflow was $0.5 million. The $2.0 million of convertible notes issued in 2019 converted into preferred stock that year; the filing reports no material ongoing financing commitments such as a credit line. Margins are not meaningful given the absence of revenue.
Material changes and notable items
- Net loss rose by $22.1 million year over year as operating expenses expanded to support clinical development, public-company operations, and pipeline growth.
- R&D expense increased $15.7 million, including $10.7 million of increased manufacturing, development, and research activity, a $3.1 million stock issuance to Elanco for expanded license rights, a $1.0 million clinical milestone payment, and higher personnel costs.
- G&A expense increased $7.0 million, driven by added personnel, legal and market-research costs, consulting, insurance, and other administrative expenses.
- The company completed its October 2020 IPO, issuing 6.325 million shares at $16.00 per share and receiving $91.7 million net proceeds. Preferred stock converted into common stock at the IPO.
- At year-end, cash and cash equivalents were substantially higher than a year earlier, while the accumulated deficit grew to $32.8 million from $6.0 million.
Outlook, risks, and contingencies
- Management expected ongoing operating losses and increasing expenses as it advanced trials and prepared for possible commercialization. It estimated year-end 2020 cash alone could fund operations into Q4 2022; including expected proceeds from the March 2021 LianBio agreement, management estimated funding into the first half of 2023. These estimates depend on assumptions and may change.
- TP-03 pivotal trial Saturn-1 began in September 2020 and was fully enrolled by Q1 2021; top-line results were expected in 2021. Saturn-2 was planned to start in Q2 2021. FDA discussions confirmed the planned NDA pathway, but FDA-recommended carcinogenicity testing and embryofetal studies in a second species, as well as a pharmacokinetic study, remained part of the development path.
- On March 26, 2021, after the reporting year, Tarsus licensed TP-03 rights for China, Hong Kong, Macau, and Taiwan to LianBio. The agreement provides for $25 million in near-term payments, up to $75 million in regulatory milestones, up to $100 million in sales milestones, royalties, and a milestone-vesting equity interest. The filing describes royalty terms inconsistently: the business summary says “low double-digits,” while the agreement discussion says “mid-to-high-teen.” Confirm the executed agreement and subsequent reporting.
- Key risks include pivotal-trial failure or delay, uncertain market size and adoption, reimbursement and pricing pressure, COVID-19 disruption, reliance on third-party manufacturers and trial organizations, and dependence on Elanco-licensed intellectual property. Management also noted the company had no commercial infrastructure and would need additional capital to fund development through approval and commercialization.
- The filing reports no material legal proceedings. Auditors issued an unmodified opinion on the financial statements; they did not audit or opine on internal control over financial reporting because of the newly public company transition period. Management concluded disclosure controls were effective at year-end.
Important facts for investors to verify
- Standalone Q4 2020 revenue, expenses, net loss, and cash flow, which are not clearly presented in this annual filing.
- Saturn-1 final results, Saturn-2 initiation and results, and completion of FDA-requested studies and other NDA requirements.
- Receipt and accounting recognition of LianBio’s $25 million near-term payments, milestone eligibility, royalty rate, and equity-interest terms.
- Cash burn and updated runway assumptions, including whether planned development, manufacturing, and launch spending require further financing.
- Supply continuity and qualification of alternative manufacturers, and compliance with Elanco license diligence and payment obligations.